A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma
- PMID: 22198210
- DOI: 10.1016/j.mrrev.2011.12.003
A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma
Abstract
Malignant pleural mesothelioma (MPM), a cancer of the serosal pleural cavities, is one of the most aggressive human tumors. In order to identify genes crucial for the onset and progression of MPM, we performed an extensive literature review focused on transcriptome studies (RTS). In this kind of studies a great number of transcripts are analyzed without formulating any a priori hypothesis, thus preventing any bias coming from previously established knowledge that could lead to an over-representation of specific genes. Each study was thoroughly analyzed paying particular attention to: (i) the employed microarray platform, (ii) the number and type of samples, (iii) the fold-change, and (iv) the statistical significance of deregulated genes. We also performed data mining (DM) on MPM using three different tools (Coremine, SNPs3D, and GeneProspector). Results from RTS and DM were compared in order to restrict the number of genes potentially deregulated in MPM. Our main requirement for a gene to be a "mesothelioma gene" (MG) is to be reproducibly deregulated among independent studies and confirmed by DM. A list of MGs was thus produced, including PTGS2, BIRC5, ASS1, JUNB, MCM2, AURKA, FGF2, MKI67, CAV1, SFRP1, CCNB1, CDK4, and MSLN that might represent potential novel biomarkers or therapeutic targets for MPM. Moreover, it was found a sub-group of MGs including ASS1, JUNB, PTGS2, EEF2, SULF1, TOP2A, AURKA, BIRC5, CAV1, IFITM1, PCNA, and PKM2 that could explain, at least in part, the mechanisms of resistance to cisplatin, one first-line chemotherapeutic drug used for the disease. Finally, the pathway analysis showed that co-regulation networks related to the cross-talk between MPM and its micro-environment, in particular involving the adhesion molecules, integrins, and cytokines, might have an important role in MPM. Future studies are warranted to better characterize the role played by these genes in MPM.
Copyright © 2011 Elsevier B.V. All rights reserved.
Similar articles
-
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.Lung Cancer. 2018 Jun;120:34-45. doi: 10.1016/j.lungcan.2018.03.022. Epub 2018 Mar 26. Lung Cancer. 2018. PMID: 29748013
-
Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.Ann Oncol. 2014 Jun;25(6):1184-92. doi: 10.1093/annonc/mdu127. Epub 2014 Mar 24. Ann Oncol. 2014. PMID: 24669013 Free PMC article.
-
MicroRNAs dysregulation in human malignant pleural mesothelioma.J Thorac Oncol. 2011 May;6(5):844-51. doi: 10.1097/JTO.0b013e31820db125. J Thorac Oncol. 2011. PMID: 21358347
-
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?Crit Rev Oncol Hematol. 2016 Nov;107:20-32. doi: 10.1016/j.critrevonc.2016.08.011. Epub 2016 Sep 1. Crit Rev Oncol Hematol. 2016. PMID: 27823648 Review.
-
Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.Microrna. 2016;5(1):12-18. doi: 10.2174/2211536605666160128151018. Microrna. 2016. PMID: 26817512 Review.
Cited by
-
Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.Drug Des Devel Ther. 2015 Jan 9;9:425-64. doi: 10.2147/DDDT.S74062. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25624750 Free PMC article.
-
Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.PLoS One. 2013 Apr 23;8(4):e61253. doi: 10.1371/journal.pone.0061253. Print 2013. PLoS One. 2013. PMID: 23626673 Free PMC article.
-
The AP-1 factor JUNB correlates with poor survival of patients with esophageal adenocarcinoma.Sci Rep. 2025 Jul 23;15(1):26790. doi: 10.1038/s41598-025-07393-9. Sci Rep. 2025. PMID: 40701988 Free PMC article.
-
Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.Cancer Res Treat. 2013 Dec;45(4):251-62. doi: 10.4143/crt.2013.45.4.251. Epub 2013 Dec 31. Cancer Res Treat. 2013. PMID: 24453997 Free PMC article. Review.
-
Biomarkers in the prevention and follow-up of workers exposed to asbestos.J Thorac Dis. 2018 Jan;10(Suppl 2):S360-S368. doi: 10.21037/jtd.2017.12.17. J Thorac Dis. 2018. PMID: 29507806 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous